Dr. Davari is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
410 Market Street #400A
CB# 7715
Chapel Hill, NC 27516
Summary
- Danielle Davari, MD is a Dermatologist based in Chapel Hill, NC. She is currently pursuing her residency at the University of North Carolina Hospitals, after receiving her medical degree from the University of North Carolina at Chapel Hill School of Medicine and completing an internship at HCA Healthcare/Mercer University School of Medicine. Prior to medical school, she received a BS degree in Quantitative Economics from Tufts University and completed a Postbaccalaureate Premedical Certificate Program at Columbia University. Dr. Davari has an extensive list of publications, relating to topics such as melanoma risk, atopic dermatitis management, and nutritional program impacts on death rates. She is also a recipient of several awards including recognition from the Gold Humanism Honor Society, the Howard Holderness Distinguished Medical Scholar award and the Medical Alumni Loyalty Fund Scholar award.
Education & Training
- University of North Carolina HospitalsResidency, Dermatology, 2023 - 2026
- HCA Healthcare/Mercer University School of MedicineInternship, Transitional Year, 2022 - 2023
- University of North Carolina at Chapel Hill School of MedicineClass of 2022
- Columbia UniversityPostbaccalaureate Premedical Certificate Program, 2014 - 2016
- Tufts UniversityBS, Quantitative Economics, Cum Laude, 2008 - 2012
Certifications & Licensure
- NC State Medical License 2023 - 2025
- SC State Medical License 2022 - 2023
Awards, Honors, & Recognition
- Gold Humanism Honor Society
- Howard Holderness Distinguished Medical Scholar
- Medical Alumni Loyalty Fund Scholar
Publications & Presentations
PubMed
- 3 citationsCombination immunotherapy including OncoVEXcreates a favorable tumor immune micro-environment in transgenic BRAF murine melanoma.Robyn D Gartrell, Zoë Blake, Emanuelle M Rizk, Rolando Perez-Lorenzo, Stuart P Weisberg
Cancer Immunology, Immunotherapy. 2022-08-01 - Association of Melanoma-Risk Variants with Primary Melanoma Tumor Prognostic Characteristics and Melanoma-Specific Survival in the GEM StudyDanielle R. Davari, Irene Orlow, Peter A. Kanetsky, Li Luo, Klaus J. Busam
Current Oncology. 2021-11-16 - 2 citationsDisease-Associated Risk Variants in ANRIL are Associated with Tumor-Infiltrating Lymphocytes Presence in Primary Melanomas in the Population-Based GEM Study.Danielle R. Davari, Irene Orlow, Peter A. Kanetsky, Li Luo, Sharon N. Edmiston
Cancer Epidemiology, Biomarkers & Prevention. 2021-10-04
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: